GSK plc

GSK plc EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of GSK plc (GSK.L) as of Nov 12, 2026 is 11.20. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 15.43 — a change of -27.43% (lower).

EV/EBIT

11.20

YoY

-27.43%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of GSK plc is 2025 11.20 . EV/EBIT (Enterprise Value to EBIT) of GSK plc was 2024 15.43 . It decreases by -27.43% lower compared to the previous year.

The GSK plc EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
11.22 GBP
Jan 1, 2020
10.67 GBP
Jan 1, 2021
16.16 GBP
Jan 1, 2022
13.07 GBP
Jan 1, 2023
12.49 GBP
Jan 1, 2024
15.43 GBP
Jan 1, 2025
11.20 GBP
Jan 1, 2026 (e)
8.49 GBP
The GSK plc EV/EBIT history
YEAREV/EBITYoY
est8.49-24.17%
11.20-27.43%
15.43+23.51%
12.49-4.45%
13.07-19.11%
16.16+51.40%
10.67-4.89%
11.22+2.78%
10.92-0.31%
10.95-14.35%
12.79-34.69%
19.58+9.82%
17.83+102.39%
8.81+8.23%
8.14+4.09%
7.82-23.33%
10.20+59.62%
6.39-6.72%
6.85-10.69%
7.67-5.07%
8.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides GSK plc's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates GSK plc's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots GSK plc's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if GSK plc grows earnings faster than its peers.

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

EV/EBIT (Enterprise Value to EBIT) of GSK plc is 11.20 in 2025.

EV/EBIT (Enterprise Value to EBIT) of GSK plc changed from 15.43 to 11.20, representing a -27.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) GSK plc since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — GSK plc

All Key Metrics — GSK plc